![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MKRN1 |
Gene summary for MKRN1 |
![]() |
Gene information | Species | Human | Gene symbol | MKRN1 | Gene ID | 23608 |
Gene name | makorin ring finger protein 1 | |
Gene Alias | RNF61 | |
Cytomap | 7q34 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q9UHC7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23608 | MKRN1 | LZE22D1 | Human | Esophagus | HGIN | 2.63e-04 | 1.70e-01 | 0.0595 |
23608 | MKRN1 | LZE22T | Human | Esophagus | ESCC | 1.22e-09 | 7.41e-01 | 0.068 |
23608 | MKRN1 | LZE24T | Human | Esophagus | ESCC | 1.76e-35 | 1.04e+00 | 0.0596 |
23608 | MKRN1 | LZE21T | Human | Esophagus | ESCC | 1.62e-02 | 4.68e-01 | 0.0655 |
23608 | MKRN1 | LZE6T | Human | Esophagus | ESCC | 2.10e-02 | -5.09e-02 | 0.0845 |
23608 | MKRN1 | P1T-E | Human | Esophagus | ESCC | 1.57e-08 | 8.04e-01 | 0.0875 |
23608 | MKRN1 | P2T-E | Human | Esophagus | ESCC | 1.02e-29 | 4.13e-01 | 0.1177 |
23608 | MKRN1 | P4T-E | Human | Esophagus | ESCC | 6.21e-46 | 1.03e+00 | 0.1323 |
23608 | MKRN1 | P5T-E | Human | Esophagus | ESCC | 3.45e-36 | 6.68e-01 | 0.1327 |
23608 | MKRN1 | P8T-E | Human | Esophagus | ESCC | 1.51e-42 | 7.90e-01 | 0.0889 |
23608 | MKRN1 | P9T-E | Human | Esophagus | ESCC | 7.27e-28 | 6.69e-01 | 0.1131 |
23608 | MKRN1 | P10T-E | Human | Esophagus | ESCC | 1.91e-42 | 7.34e-01 | 0.116 |
23608 | MKRN1 | P11T-E | Human | Esophagus | ESCC | 2.19e-12 | 5.51e-01 | 0.1426 |
23608 | MKRN1 | P12T-E | Human | Esophagus | ESCC | 2.62e-60 | 1.12e+00 | 0.1122 |
23608 | MKRN1 | P15T-E | Human | Esophagus | ESCC | 1.67e-74 | 1.78e+00 | 0.1149 |
23608 | MKRN1 | P16T-E | Human | Esophagus | ESCC | 3.85e-37 | 7.17e-01 | 0.1153 |
23608 | MKRN1 | P17T-E | Human | Esophagus | ESCC | 6.76e-05 | 3.54e-01 | 0.1278 |
23608 | MKRN1 | P19T-E | Human | Esophagus | ESCC | 5.40e-06 | 6.93e-01 | 0.1662 |
23608 | MKRN1 | P20T-E | Human | Esophagus | ESCC | 5.38e-11 | 2.41e-01 | 0.1124 |
23608 | MKRN1 | P21T-E | Human | Esophagus | ESCC | 1.20e-38 | 8.87e-01 | 0.1617 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0000209 | Colorectum | AD | protein polyubiquitination | 78/3918 | 236/18723 | 8.71e-06 | 2.06e-04 | 78 |
GO:00002092 | Colorectum | MSS | protein polyubiquitination | 72/3467 | 236/18723 | 5.19e-06 | 1.42e-04 | 72 |
GO:00002093 | Colorectum | FAP | protein polyubiquitination | 59/2622 | 236/18723 | 4.53e-06 | 1.52e-04 | 59 |
GO:000020916 | Esophagus | HGIN | protein polyubiquitination | 58/2587 | 236/18723 | 6.29e-06 | 1.97e-04 | 58 |
GO:000020917 | Esophagus | ESCC | protein polyubiquitination | 170/8552 | 236/18723 | 1.40e-16 | 1.09e-14 | 170 |
GO:000020911 | Liver | Cirrhotic | protein polyubiquitination | 89/4634 | 236/18723 | 6.09e-06 | 9.80e-05 | 89 |
GO:000020921 | Liver | HCC | protein polyubiquitination | 151/7958 | 236/18723 | 1.90e-11 | 7.59e-10 | 151 |
GO:000020910 | Oral cavity | OSCC | protein polyubiquitination | 150/7305 | 236/18723 | 1.59e-14 | 9.27e-13 | 150 |
GO:000020915 | Oral cavity | LP | protein polyubiquitination | 82/4623 | 236/18723 | 3.23e-04 | 3.26e-03 | 82 |
GO:00002099 | Prostate | BPH | protein polyubiquitination | 64/3107 | 236/18723 | 2.83e-05 | 3.31e-04 | 64 |
GO:000020914 | Prostate | Tumor | protein polyubiquitination | 64/3246 | 236/18723 | 1.08e-04 | 1.03e-03 | 64 |
GO:000020924 | Skin | cSCC | protein polyubiquitination | 103/4864 | 236/18723 | 2.57e-09 | 9.09e-08 | 103 |
GO:000020920 | Thyroid | PTC | protein polyubiquitination | 128/5968 | 236/18723 | 7.81e-13 | 3.65e-11 | 128 |
GO:0000209110 | Thyroid | ATC | protein polyubiquitination | 134/6293 | 236/18723 | 1.86e-13 | 9.20e-12 | 134 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MKRN1 | SNV | Missense_Mutation | c.1294N>A | p.Phe432Ile | p.F432I | Q9UHC7 | protein_coding | deleterious(0.02) | possibly_damaging(0.758) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
MKRN1 | SNV | Missense_Mutation | c.1336N>A | p.Glu446Lys | p.E446K | Q9UHC7 | protein_coding | tolerated(0.19) | benign(0.05) | TCGA-C8-A12P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MKRN1 | insertion | Nonsense_Mutation | novel | c.572_573insTTGTATTGAATGACAGGAAGAGATCC | p.Gln192CysfsTer4 | p.Q192Cfs*4 | Q9UHC7 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
MKRN1 | SNV | Missense_Mutation | rs765877418 | c.542G>A | p.Arg181His | p.R181H | Q9UHC7 | protein_coding | deleterious(0) | benign(0.152) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MKRN1 | SNV | Missense_Mutation | c.1336N>A | p.Glu446Lys | p.E446K | Q9UHC7 | protein_coding | tolerated(0.19) | benign(0.05) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
MKRN1 | SNV | Missense_Mutation | novel | c.73N>A | p.Ala25Thr | p.A25T | Q9UHC7 | protein_coding | tolerated(0.28) | benign(0.014) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
MKRN1 | SNV | Missense_Mutation | c.286N>A | p.Gly96Arg | p.G96R | Q9UHC7 | protein_coding | tolerated(0.07) | benign(0.137) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
MKRN1 | SNV | Missense_Mutation | novel | c.1375G>A | p.Glu459Lys | p.E459K | Q9UHC7 | protein_coding | tolerated(0.13) | benign(0.011) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MKRN1 | SNV | Missense_Mutation | rs528516903 | c.254C>T | p.Pro85Leu | p.P85L | Q9UHC7 | protein_coding | tolerated(0.1) | benign(0.011) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MKRN1 | SNV | Missense_Mutation | rs376798349 | c.824G>A | p.Arg275His | p.R275H | Q9UHC7 | protein_coding | tolerated(0.08) | benign(0.066) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |